Skip to main content

Oregon State Flag An official website of the State of Oregon »

Oregon.gov Homepage

Monoclonal antibody therapy (mAb)

Provider Operations ManualManual para ProveedoresTest to Treat LocatorCOVID-19 Therapeutics Locator

Important Updates


Bebtelovimab
  • Bebtelovimab is now commercially available for purchase
    • Providers can order directly through their AmerisourceBergen accounts . If you do not have an AmerisourceBergen account, contact service@asdhealthcare.com
    • CMS updated their monoclonal antibodies payment structure for Bebtelovimab 
    • Reporting inventory and utilization in HPOP is still mandatory for all supply received by Oregon Health Authority
  • The Oregon Health Authority has limited stock of Bebtelovimab but will continue distribution of the product to Oregon providers until stock is depleted
    • OHA is committed to equitable distribution of the limited stock that remains
    • OHA may not be able to fulfill 100% of the courses requested for all providers.
    • Providers who receive OHA supply must continue to report inventory and utilization in HPOP
Evusheld
  • FDA authorizes revisions to Evusheld re-dosing and Evusheld shelf life extensions.
    • The AstraZeneca Call Center remains available should providers have questions regarding the updated dosing guidance and/or the shelf-life extension for Evusheld. The AstraZeneca Call Center can be reached at 1-800-236-9933
  • Evusheld can now be directly ordered in small quantities for individual providers through this form: OrderEvusheld.com
    • Evusheld is now available at some Federally Registered Pharmacy Partners for patients with an Evusheld prescription
    • Please check the COVID-19 Therapeutics Locator to find pharmacies that have Evusheld
    • Please call ahead to ensure services are available
General


​Tixagevimab/Cilgavimab (Evusheld)

  • ​Preexposure prevention of COVID-19
  • Given into the muscle
  • For people not currently infected, no recent exposure, and
    • Moderate to severe immunocompromise, or
    • Can't get vaccinated for medical reasons (severe allergy)

​​Bebtelovimab​

  • Treatment of mild-to-moderate COVID-19 illness
  • Given by vein, within 7 days of symptom onset
  • For people with a positive test, at high risk for severe COVID-19 and no access to other FDA-authorized treatments

All providers are now eligible to order both Euvhseld and Bebtelovimab. OHA remains committed to equitable distribution of all therapeutics, however, due to supply fluctuations, OHA may not be able to fulfill 100% of the courses requested. ​​​


Bebtelovimab is now commercially available for purchase

  • Providers can order directly through their AmerisourceBergen accounts. If you do not have an AmerisourceBergen account, contact service@asdhealthcare.com.
  • CMS updated their monoclonal antibodies payment structure for Bebtelovimab 
  • Reporting inventory and utilization in HPOP is still mandatory for all supply received by Oregon Health Authority 

​Evusheld can now be directly ordered in small quantities for individual providers through this form: OrderEvusheld.com 


To order Evusheld or remaining supply of Bebtelovimab from OHA, follow the below instructions:

  • Submit order requests directly in Health Partner Ordering Portal​ (HPoP)​

  • Surveys are due on Wednesdays by 11:59 pm to be considered for the current weekly allocation. Surveys submitted after the due date will be considered for the next allocation cycle. 
  • ​​​​Please refer to the below additional resources to assist in the ordering process. These can aslo be found on this page under the "Healthcare Provider Resources" section. 


        Weekly federal allocations

        Sites receiving mAb therapy
        For specific information regarding sites that have therapeutics supply, please utilize the COVID-19 Therapeutics Locator. If you are an ordering provider, please check your email inbox for the weekly site allocation spreadsheet.


        Notes:

        Allocations are prioritized to ordering sites weekly, based on the following considerations:

        • Federally Qualified Health Centers & Tribal Health Clinics, which serve communities disproportionately impacted by COVID-19
        • County-level COVID-19 hospitalizations & cases 
        • Sites located in communities disproportionately impacted by COVID-19 (utilizing COVID-19 Community Vulnerability Index)
        • Site-level weekly utilization rate

        Download the list



         Contact Us

        oha.therapeutics@odhsoha.oregon.gov

         Healthcare Provider Resources

        OHA Resources

        COVID-19 Therapeutics Newsletters

        September 2022
        August 2022
        July 2022
        June 2022

        Webinars for Providers

        August 19, 2021 - OHA COVID-19 Senior Health Advisors Dawn Maunter, MD, MS and Shimi Sharief, MD, MPH

        Watch the webinarDownload the slides

        March 10, 2022 - OHA Outreach Coordinator Greg Desrosiers Sr. and Panelists

        Watch the webinarDownload the slides

        July 22, 2022 - OHA Outreach Coordinator Greg Desrosiers Sr. and Panelists

        Watch the webinarDownload the slides

        HHS Resources

         Patient Resources

         Visit our treatments page